Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent
CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Gyeongsang National University Hospital Hallym University Medical Center Kyunghee University Medical Center Seoul National University Bundang Hospital